Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncternal Therapeutics Inc reports Q1 loss but advances promising therapies

Oncternal Therapeutics Inc's Q1 2024 performance reflects ongoing investment in innovative therapies amidst a net loss of $8.4 million.
The company's financial stability, upcoming milestones, and engagement with analysts position it well for future growth and development.
Challenges in managing expenses, meeting clinical data timelines, and ensuring therapeutic success underscore the need for strategic decision-making and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of two abstracts at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4-8, 2021.

Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies.

Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of three posters at the American Association for Cancer Research (AACR) 2021 Annual Meeting being held virtually from April 10-15, 2021.

Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting

As of late, it has definitely been a great time to be an investor in Oncternal Therapeutics, Inc. (ONCT).

Oncternal Therapeutics' (ONCT) Shares March Higher, Can It Continue?

Oncternal Therapeutics (ONCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?

This analyst is excited about the company's prospects.

Why Oncternal Therapeutics Stock Is Popping Today

Amtech Systems

Aytu BioScience

Avid Bioservices

Interactive Brokers

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

5 Stocks to Buy on New Analyst Coverage

Investors need to pay close attention to Oncternal Therapeutics (ONCT) stock based on the movements in the options market lately.

Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options

Oncternal Therapeutics is one of the few companies with clinical assets targeting ROR-1. Recent M&As for two ROR-1 companies by Merck and Boehringer Ingelheim have set a market value around $1B-$2B.

Oncternal Therapeutics: Opportunistic Investment In A ROR-1 Biotech

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Anita Wiseth, who joined the company as Senior Vice President, Human Resources.

Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2020 financial results.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results

Oncternal is one of the oldest companies in the ROR1 oncology space, a field fraught with recent acquisitions. Almost every other player in the ROR1 space has been scooped up by big pharma players, but mostly those in ADCs.

Oncternal Therapeutics: Improving Outcomes In 'Standard Of Care' Chemo

Organogenesis Holdings

Schnitzer Steel Industries Inc

Turning Point Therapeutics

USANA Health Sciences

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Oncternal has solid data for cirmtuzumab+ibrutinib in MCL and CLL. It has cash it says is enough for 2 years.

Oncternal: Solid Data In Tough-To-Treat Cancer

Oncternal has potential winner with cirmtuzumab in mantle cell lymphoma. A potential pediatric review voucher for TK216 in Ewing sarcoma alone is worth $80-150 million.

Oncternal Therapeutics: Recent Success Points To A Bright Future

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Rosemary Mazanet, M.D., Ph.D., to its Board of Directors, effective January 27, 2021. Dr. Mazanet has extensive experience in all stages of oncology drug development from investigational new drug submission (“IND”) through new drug application (“NDA”) approval and commercial launch.

Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal's investigational ROR1-targeting CAR-T cell therapy program.

Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

SAN DIEGO and STOCKHOLM, Sweden, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it established a research and development collaboration with world-renowned Karolinska Institutet in Stockholm, Sweden, to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK (Natural Killer) cells from the laboratory into the clinic.

Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the closing of its previously announced public offering on a firm commitment basis of 19,161,667 shares of common stock of the Company, including the exercise in full by the underwriter of its option to purchase an additional 2,495,000 shares of common stock, at a price to the public of $4.50 per share, less underwriting discounts and commissions.

Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 16,666,667 shares of common stock of the Company, at a price to the public of $4.50 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 14, 2020, subject to satisfaction of customary closing conditions.

Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,888,889 shares of common stock of the Company, at a price to the public of $4.50 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 14, 2020, subject to satisfaction of customary closing conditions.

Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 7,258,065 shares of common stock of the Company, at a price to the public of $3.10 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 20, 2020, subject to satisfaction of customary closing conditions.

Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 6,451,613 shares of common stock of the Company, at a price to the public of $3.10 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 20, 2020, subject to satisfaction of customary closing conditions.

Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from its ongoing Phase 1 clinical trial evaluating TK216, an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. The data update will be delivered in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting, and a copy of the presentation will be available online at www.oncternal.com starting on November 11, 2020.

Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting

News for Oncternal Therapeutics Inc Stock (ONCT)